Etanercept, a tumor necrosis factor-alpha (TNF-α) inhibitor, suppresses key inflammatory responses, masking classic CNF signs such as erythema, bullae, or crepitation, which are present in 70-80% of cases [4,5]. The gene discussed is TNF; the disease is Erythema.